Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study

This retrospective cohort study evaluated the effectiveness and safety of anlotinib versus bevacizumab, both combined with taxane/capecitabine, in 130 patients with HER-2-negative metastatic breast cancer undergoing second-line or subsequent treatment. The study found that the anlotinib group had a higher disease control rate (86.57% vs. 69.84%) and longer median progression-free survival (8.57 vs. 5.90 months) and overall survival (22.76 vs. 16.50 months) compared to the bevacizumab group. Both treatments had manageable safety profiles, with common adverse events including alopecia and peripheral neuropathy. The findings suggest anlotinib as a promising option, though further studies are needed for confirmation.